R
Robert O. Carpenter
Publications - 7
Citations - 2437
Robert O. Carpenter is an academic researcher. The author has contributed to research in topics: Antigen & Chronic lymphocytic leukemia. The author has an hindex of 5, co-authored 6 publications receiving 2118 citations.
Papers
More filters
Journal ArticleDOI
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer,Mark E. Dudley,Sadik H. Kassim,Robert Somerville,Robert O. Carpenter,Maryalice Stetler-Stevenson,James Chih-Hsin Yang,Giao Q. Phan,Michael S. Hughes,Richard M. Sherry,Mark Raffeld,Steven R. Feldman,Lily Lu,Yong F. Li,Lien T. Ngo,Andre Goy,Tatyana Feldman,David Spaner,Michael L. Wang,Clara C. Chen,Sarah M. Kranick,Avindra Nath,Debbie-Ann N. Nathan,Kathleen E. Morton,Mary Ann Toomey,Steven A. Rosenberg +25 more
TL;DR: The results demonstrate the feasibility and effectiveness of treating chemotherapy-refractory B-cell malignancies with anti-CD19 CAR T cells and provide strong support for further development of this approach.
Journal ArticleDOI
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter,Moses O. Evbuomwan,Stefania Pittaluga,Jeremy J. Rose,Mark Raffeld,Shicheng Yang,Ronald E. Gress,Frances T. Hakim,James N. Kochenderfer +8 more
TL;DR: This work designed and tested the first anti-BCMA CARs to be reported and transduced T cells with lentiviral vectors encoding these CARs that exhibited BCMA-specific functions including cytokine production, proliferation, cytotoxicity, and in vivo tumor eradication.
Journal ArticleDOI
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
James N. Kochenderfer,Mark E. Dudley,Robert O. Carpenter,Sadik H. Kassim,Jeremy J. Rose,William G. Telford,Frances T. Hakim,David Halverson,Daniel H. Fowler,Nancy M. Hardy,Anthony R. Mato,Dennis D. Hickstein,Juan Gea-Banacloche,Steven Z. Pavletic,Claude Sportes,Irina Maric,Steven A. Feldman,Brenna Hansen,Jennifer Wilder,Bazetta Blacklock-Schuver,Bipulendu Jena,Michael R. Bishop,Ronald E. Gress,Steven A. Rosenberg +23 more
TL;DR: Results show for the first time that donor-derived allogeneic anti-CD19-CAR T cells can cause regression of B-cell malignancies resistant to standard DLIs without causing GVHD.
Journal ArticleDOI
Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation
James N. Kochenderfer,Mark E. Dudley,Robert O. Carpenter,Sadik H. Kassim,Jeremy J. Rose,William G. Telford,Frances T. Hakim,David Halverson,Daniel H. Fowler,Nancy M. Hardy,Anthony R. Mato,Dennis D. Hickstein,Juan Gea-Banacloche,Steven Z. Pavletic,Claude Sportes,Irina Maric,Steven R. Feldman,Brenna Hansen,Jennifer Wilder,Bazetta Blacklock-Schuver,Bipulendu Jena,Michael R. Bishop,Steven A. Rosenberg,Ronald E. Gress +23 more
TL;DR: None of the patients treated on this study developed GVHD after their anti-CD19-CAR-T-cell infusions, despite the fact that 6 of 10 treated patients had experienced GV HD at earlier time-points after their most recent alloHSCT.
Journal ArticleDOI
Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor
Mark E. Dudley,Sadik H. Kassim,Robert O. Carpenter,James Chih-Hsin Yang,Giao Q. Phan,Michael S. Hughes,Richard M. Sherry,Steven R. Feldman,David Spaner,Debbie-Ann N. Nathan,Kathleen E. Morton,Mary Ann Toomey,Steven A. Rosenberg +12 more
TL;DR: The results demonstrate the feasibility of treating patients with chemotherapy-refractory B-cell malignancies by using autologous anti-CD19 CAR T cells and the numerous remissions obtained should encourage further development of this approach.